Christoph Oing

4.2k total citations · 2 hit papers
84 papers, 2.1k citations indexed

About

Christoph Oing is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Christoph Oing has authored 84 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Surgery, 28 papers in Pulmonary and Respiratory Medicine and 21 papers in Molecular Biology. Recurrent topics in Christoph Oing's work include Testicular diseases and treatments (54 papers), Sarcoma Diagnosis and Treatment (15 papers) and Neuroblastoma Research and Treatments (14 papers). Christoph Oing is often cited by papers focused on Testicular diseases and treatments (54 papers), Sarcoma Diagnosis and Treatment (15 papers) and Neuroblastoma Research and Treatments (14 papers). Christoph Oing collaborates with scholars based in Germany, United Kingdom and Switzerland. Christoph Oing's co-authors include Carsten Bokemeyer, Silke Gillessen, Robert G. Bristow, Robert E. Reiter, Karen E. Knudsen, David C. Johnson, Theodorus van der Kwast, Richard J. Rebello, Stacy Loeb and Karin Oechsle and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and Scientific Reports.

In The Last Decade

Christoph Oing

76 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prostate cancer

2021 663 citations Christoph Oing, Robert G. Bristow et al. profile →
European Association of Urology Guidelines on Testicular Cancer: 2023 Update

2023 99 citations Christian D. Fankhauser, Christoph Oing et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christoph Oing Germany	23	876	846	745	521	376	84	2.1k
Stefan Hinz Germany	25	830 0.9×	364 0.4×	767 1.0×	401 0.8×	317 0.8×	98	1.9k
Myrna Candelaria Mexico	25	1.4k 1.6×	336 0.4×	272 0.4×	563 1.1×	243 0.6×	88	2.5k
Carolyn Y. Muller United States	35	1.2k 1.4×	592 0.7×	378 0.5×	972 1.9×	504 1.3×	104	3.4k
S.J. Harland United Kingdom	21	511 0.6×	859 1.0×	668 0.9×	664 1.3×	119 0.3×	39	2.2k
Michele Aieta Italy	24	638 0.7×	315 0.4×	997 1.3×	1.2k 2.3×	600 1.6×	116	2.3k
Monika Klinkhammer‐Schalke Germany	27	567 0.6×	616 0.7×	552 0.7×	1.4k 2.7×	607 1.6×	171	2.9k
Cinzia Orlandini Italy	29	622 0.7×	748 0.9×	877 1.2×	2.2k 4.2×	630 1.7×	74	3.7k
Christian Wülfing Germany	22	629 0.7×	634 0.7×	786 1.1×	508 1.0×	356 0.9×	113	1.9k
Mikio Mikami Japan	30	623 0.7×	704 0.8×	279 0.4×	547 1.0×	317 0.8×	217	3.3k
Jay B. Shah United States	28	620 0.7×	1.4k 1.6×	532 0.7×	715 1.4×	239 0.6×	84	2.6k

Countries citing papers authored by Christoph Oing

Since Specialization

Citations

This map shows the geographic impact of Christoph Oing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christoph Oing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christoph Oing more than expected).

Fields of papers citing papers by Christoph Oing

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christoph Oing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christoph Oing. The network helps show where Christoph Oing may publish in the future.

Co-authorship network of co-authors of Christoph Oing

This figure shows the co-authorship network connecting the top 25 collaborators of Christoph Oing. A scholar is included among the top collaborators of Christoph Oing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christoph Oing. Christoph Oing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hardy, Claire, Moira O’Connor, Élena Elez, et al.. (2025). Oncology professionals’ perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series. ESMO Open. 10(3). 104298–104298.

Oing, Christoph, Christoph Seidel, A. Tryakin, et al.. (2024). 704P Characteristics and palliative management of patients with cisplatin-refractory germ cell tumours: A Global Germ Cell Cancer Collaborative Group (G3) retrospective registry study. Annals of Oncology. 35. S541–S542.

Seidel, Christoph, Elizabeth A. Connolly, Peter Grimison, et al.. (2024). Efficacy and safety of high-dose chemotherapy as the first or subsequent salvage treatment line in patients with relapsed or refractory germ cell cancer: an international multicentric analysis. ESMO Open. 9(5). 103449–103449. 2 indexed citations

Oing, Christoph, Christoph Seidel, Pasquale Rescigno, et al.. (2024). Hyperthyroidism in non-seminomatous testicular germ cell tumors: two case reports and literature review. Frontiers in Oncology. 14. 1338438–1338438. 1 indexed citations

Lim, Kok Haw Jonathan, Konstantinos Kamposioras, Élena Elez, et al.. (2024). ESMO Resilience Task Force recommendations to manage psychosocial risks, optimise well-being, and reduce burnout in oncology. ESMO Open. 9(10). 103634–103634. 3 indexed citations

Oing, Christoph, Susanne Burdak‐Rothkamm, Malik Alawi, et al.. (2023). Preclinical patient‐derived modeling of castration‐resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease. Molecular Oncology. 17(6). 1129–1147. 4 indexed citations

Oing, Christoph & Robert G. Bristow. (2023). Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open. 8(2). 101194–101194. 8 indexed citations

Messina, Carlo, Emilio Francesco Giunta, Alessio Signori, et al.. (2023). Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis. European Urology Oncology. 7(2). 179–188. 22 indexed citations

Holzgreve, Adrien, Matthias Mäurer, Florian T. Gassert, et al.. (2023). Therapiemonitoring der neoadjuvanten Radio‑/Chemotherapie. GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen). 29(12). 1043–1051. 1 indexed citations

10.

Mair, Maximilian J., Elizabeth A. Connolly, Maria Kfoury, et al.. (2022). Career and Professional Development for Young Oncologists. Oncology Research and Treatment. 46(3). 67–71. 2 indexed citations

11.

Chovanec, Michal, Jakob Lauritsen, Mikkel Bandak, et al.. (2021). Late adverse effects and quality of life in survivors of testicular germ cell tumour. Nature Reviews Urology. 18(4). 227–245. 51 indexed citations

12.

Skowron, Margaretha A., Christoph Oing, Felix Bremmer, et al.. (2021). The developmental origin of cancers defines basic principles of cisplatin resistance. Cancer Letters. 519. 199–210. 29 indexed citations

13.

Richter, Annika, Stefan Kircher, Andreas Rosenwald, et al.. (2021). Primary mediastinal germ cell tumours: an immunohistochemical and molecular diagnostic approach. Histopathology. 80(2). 381–396. 16 indexed citations

14.

Miranda‐Gonçalves, Vera, João Lobo, Daniela Barros‐Silva, et al.. (2021). The component of the m6A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors. Journal of Experimental & Clinical Cancer Research. 40(1). 268–268. 37 indexed citations

15.

Banerjee, Susana, Kok Haw Jonathan Lim, Krithika Murali, et al.. (2021). The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration. ESMO Open. 6(2). 100058–100058. 39 indexed citations

16.

Lobo, João, Daniela Barros‐Silva, Vera Miranda‐Gonçalves, et al.. (2020). Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors. Cancers. 12(10). 2903–2903. 26 indexed citations

17.

Richter, Annika, Nadine T. Gaisa, Stefan Schweyer, et al.. (2020). The detection of isochromosome i(12p) in malignant germ cell tumours and tumours with somatic malignant transformation by the use of quantitative real‐time polymerase chain reaction. Histopathology. 78(4). 593–606. 39 indexed citations

18.

Banerjee, Susana, Kok Haw Jonathan Lim, Krithika Murali, et al.. (2020). LBA70_PR The impact of COVID-19 on oncology professionals: Initial results of the ESMO resilience task force survey collaboration. Annals of Oncology. 31. S1200–S1201. 6 indexed citations

19.

Oing, Christoph, Margaretha A. Skowron, Carsten Bokemeyer, & Daniel Nettersheim. (2019). Epigenetic treatment combinations to effectively target cisplatin‐resistant germ cell tumors: past, present, and future considerations. Andrology. 7(4). 487–497. 25 indexed citations

20.

Oing, Christoph & Anja Lorch. (2018). The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors. Oncology Research and Treatment. 41(6). 365–369. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact